If this study can clinically confirm the hypothesis that individuals with ATM-deficiency respond well to either metformin or pioglitazone, and individuals show marked improvement in insulin resistance while taking either study drug, this study could direct clinical decision-making in the care of patients with A-T and fatty liver / insulin resistance.